Inflammatory bowel disease articles from across Nature Portfolio

Nutrient competition is a major obstacle to probiotic survival and success in treating inflammatory bowel disease. Here, the authors report on an ameba-inspired food-carrying strategy developed to provide a prebound food supply, free from competition, to improve probiotic survival increasing therapeutic potential.

Sphingosine-1-phosphate receptor 1 (S1PR1) is a drug target for inflammatory bowel disease (IBD), impacting immune cell movement, but current treatments carry immunosuppression risks. Here, the authors show that a Gi-biased S1PR1 agonist, SAR247799, protects the endothelial barrier in IBD models without affecting immune cell egress, offering a potential new treatment strategy.

Biological sex has a vital role in the pathogenesis of inflammatory bowel disease (IBD). This Review examines sex in IBD pathophysiology and clinical manifestation and provides a frame for improving clinical and preclinical IBD studies by considering sex an essential factor.

Patients with inflammatory bowel disease (IBD) have increased risk for venous thromboembolism, but mechanistic insight is still lacking. Using both mouse experimental colitis models and IBD patient biopsies, here the authors implicate increased tissue factor activity on colitogenic T cells as a potential link.

In 2024, there were major advances in inflammatory bowel disease research. Treatment strategies with biologic agents for inflammatory bowel disease matured, and gut microbiota–bacteriophage–host interaction emerged as a new frontier to target.

Therapeutic advances in inflammatory bowel disease (IBD) have been universally directed towards patients with established disease to control inflammation, ameliorate symptoms and hinder disease progression, but preventing IBD development or delaying its onset are highly attractive. This Comment discusses the emerging approaches and future promises of interventional disease prevention trials in IBD.

Bathroom ban legislation is increasing throughout the United States, and little is known about the effect on transgender and gender-nonconforming individuals with chronic gastrointestinal conditions. Efforts should be made to raise awareness and address the knowledge gaps.

Risankizumab outperformed ustekinumab for the treatment of moderate to severe Crohn’s disease in patients refractory to anti-TNF therapy.

Patients with Crohn’s disease display an altered serum IgG glycosylation signature that is detectable many years before clinical diagnosis and is associated with increased levels of pathogenic anti-mannan antibodies. The altered IgG glycoforms activate innate immune cells, in a preclinical phase, promoting the transition to intestinal inflammation.